{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":83,"searchCount":0},"additional":{"submitter":["Marzi A"],"funding":["National Institute of Allergy and Infectious Diseases","Intramural NIH HHS","Health and Labour Sciences Research Grants, Japan","NIAID NIH HHS","NIH"],"pagination":["439-42"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4565490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["348(6233)"],"pubmed_abstract":["Zaire ebolavirus is the causative agent of the current outbreak of hemorrhagic fever disease in West Africa. Previously, we showed that a whole Ebola virus (EBOV) vaccine based on a replication-defective EBOV (EBOVΔVP30) protects immunized mice and guinea pigs against lethal challenge with rodent-adapted EBOV. Here, we demonstrate that EBOVΔVP30 protects nonhuman primates against lethal infection with EBOV. Although EBOVΔVP30 is replication-incompetent, we additionally inactivated the vaccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in nonhuman primates. EBOVΔVP30 thus represents a safe, efficacious, whole-EBOV vaccine candidate that differs from other EBOV vaccine platforms in that it presents all viral proteins and the viral RNA to the host immune system, which might contribute to protective immune responses."],"journal":["Science (New York, N.Y.)"],"pubmed_title":["Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates."],"pmcid":["PMC4565490"],"funding_grant_id":["U54 AI 57153","U54 AI057153"],"pubmed_authors":["Hill-Batorski L","Kawaoka Y","Marzi A","Shupert WL","Halfmann P","Feldmann F","Neumann G","Feldmann H"],"view_count":["83"],"additional_accession":[]},"is_claimable":false,"name":"Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.","description":"Zaire ebolavirus is the causative agent of the current outbreak of hemorrhagic fever disease in West Africa. Previously, we showed that a whole Ebola virus (EBOV) vaccine based on a replication-defective EBOV (EBOVΔVP30) protects immunized mice and guinea pigs against lethal challenge with rodent-adapted EBOV. Here, we demonstrate that EBOVΔVP30 protects nonhuman primates against lethal infection with EBOV. Although EBOVΔVP30 is replication-incompetent, we additionally inactivated the vaccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in nonhuman primates. EBOVΔVP30 thus represents a safe, efficacious, whole-EBOV vaccine candidate that differs from other EBOV vaccine platforms in that it presents all viral proteins and the viral RNA to the host immune system, which might contribute to protective immune responses.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Apr","modification":"2024-02-15T16:15:42.742Z","creation":"2019-03-27T01:58:10Z"},"accession":"S-EPMC4565490","cross_references":{"pubmed":["25814063"],"doi":["10.1126/science.aaa4919"]}}